HPS Pharmacies wish to give notice that all suppliers are experiencing a supply interruption for cefalexin powder for oral liquid as follows:
|Product||ARTG||Estimated Return Date|
|Cefalexin Sandoz 125mg/5mL||78981||End January 2023|
|Cefalexin Sandoz 250mg/5mL||78982||Mid-January 2023|
|Ibilex® 125mg/5mL||92972||End January 2023|
|Ibilex® 250mg/5mL||92973||End February 2023|
|Keflex® 125mg/5mL||92970||End December 2022|
|Keflex® 250mg/5mL||92971||End December 2022|
The Therapeutic Goods Administration (TGA) has made a Serious Scarcity Substitution Instrument (SSSI) to help manage this out of stock situation. The SSSI allows pharmacists to substitute an alternative cefalexin syrup or suspension when the prescribed one is unavailable. Alternatively, cefalexin 250mg capsules may be given if the patient can swallow a capsule and the dose is divisible by 250.
This SSSI is in force until 31 July 2023, unless revoked earlier by the TGA.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates